These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1137 related articles for article (PubMed ID: 12794819)

  • 1. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis.
    Nakahara H; Song J; Sugimoto M; Hagihara K; Kishimoto T; Yoshizaki K; Nishimoto N
    Arthritis Rheum; 2003 Jun; 48(6):1521-9. PubMed ID: 12794819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
    Paleolog EM; Young S; Stark AC; McCloskey RV; Feldmann M; Maini RN
    Arthritis Rheum; 1998 Jul; 41(7):1258-65. PubMed ID: 9663484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph draining from foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine production and transport to lymph nodes.
    Olszewski WL; Pazdur J; Kubasiewicz E; Zaleska M; Cooke CJ; Miller NE
    Arthritis Rheum; 2001 Mar; 44(3):541-9. PubMed ID: 11263768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-18 induces the production of vascular endothelial growth factor (VEGF) in rheumatoid arthritis synovial fibroblasts via AP-1-dependent pathways.
    Cho ML; Jung YO; Moon YM; Min SY; Yoon CH; Lee SH; Park SH; Cho CS; Jue DM; Kim HY
    Immunol Lett; 2006 Mar; 103(2):159-66. PubMed ID: 16368150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does vascular endothelial growth factor play a role in interleukin-6 receptor antagonist therapy for rheumatoid arthritis?
    Gentiletti J; Fava RA
    Arthritis Rheum; 2003 Jun; 48(6):1471-4. PubMed ID: 12794810
    [No Abstract]   [Full Text] [Related]  

  • 6. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis.
    Kim HR; Park MK; Cho ML; Yoon CH; Lee SH; Park SH; Leng L; Bucala R; Kang I; Choe J; Kim HY
    J Rheumatol; 2007 May; 34(5):927-36. PubMed ID: 17407222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta.
    Jackson JR; Minton JA; Ho ML; Wei N; Winkler JD
    J Rheumatol; 1997 Jul; 24(7):1253-9. PubMed ID: 9228120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane.
    Hosaka K; Ryu J; Saitoh S; Ishii T; Kuroda K; Shimizu K
    Cytokine; 2005 Dec; 32(6):263-9. PubMed ID: 16406555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of pleiotrophin, an embryonic growth and differentiation factor, in rheumatoid arthritis.
    Pufe T; Bartscher M; Petersen W; Tillmann B; Mentlein R
    Arthritis Rheum; 2003 Mar; 48(3):660-7. PubMed ID: 12632418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Piascledine modulates the production of VEGF and TIMP-1 and reduces the invasiveness of rheumatoid arthritis synoviocytes.
    Cinelli M; Guiducci S; Del Rosso A; Pignone A; Del Rosso M; Fibbi G; Serratì S; Gabrielli A; Giacomelli R; Piccardi N; Matucci Cerinic M
    Scand J Rheumatol; 2006; 35(5):346-50. PubMed ID: 17062432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Responses to the proinflammatory cytokines interleukin-1 and tumor necrosis factor alpha in cells derived from rheumatoid synovium and other joint tissues involve nuclear factor kappaB-mediated induction of the Ets transcription factor ESE-1.
    Grall F; Gu X; Tan L; Cho JY; Inan MS; Pettit AR; Thamrongsak U; Choy BK; Manning C; Akbarali Y; Zerbini L; Rudders S; Goldring SR; Gravallese EM; Oettgen P; Goldring MB; Libermann TA
    Arthritis Rheum; 2003 May; 48(5):1249-60. PubMed ID: 12746898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased expression of Fcgamma receptors II and III on macrophages of rheumatoid arthritis patients results in higher production of tumor necrosis factor alpha and matrix metalloproteinase.
    Blom AB; Radstake TR; Holthuysen AE; Slöetjes AW; Pesman GJ; Sweep FG; van de Loo FA; Joosten LA; Barrera P; van Lent PL; van den Berg WB
    Arthritis Rheum; 2003 Apr; 48(4):1002-14. PubMed ID: 12687542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes.
    Cha HS; Bae EK; Koh JH; Chai JY; Jeon CH; Ahn KS; Kim J; Koh EM
    J Rheumatol; 2007 Jan; 34(1):16-9. PubMed ID: 17216674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
    Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC
    Arthritis Rheum; 2000 Nov; 43(11):2391-6. PubMed ID: 11083259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kappaB using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis.
    Harigai M; Hara M; Kawamoto M; Kawaguchi Y; Sugiura T; Tanaka M; Nakagawa M; Ichida H; Takagi K; Higami-Ohsako S; Shimada K; Kamatani N
    Arthritis Rheum; 2004 Jul; 50(7):2167-77. PubMed ID: 15248214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis.
    Matsukawa A; Yoshimura T; Maeda T; Takahashi T; Ohkawara S; Yoshinaga M
    Lab Invest; 1998 May; 78(5):559-69. PubMed ID: 9605181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
    Chabaud M; Miossec P
    Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes.
    Cho ML; Kim WU; Min SY; Min DJ; Min JK; Lee SH; Park SH; Cho CS; Kim HY
    Arthritis Rheum; 2002 Jan; 46(1):42-51. PubMed ID: 11817607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of RNAi on cyclooxygenase-2 expression and biologic activity of human rheumatoid arthritis synovial fibroblasts].
    Jiang LD; Wang HZ; Zhao FD; Guo JS; Bao CD; Zou HJ; Wang JY
    Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2925-8. PubMed ID: 18261308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.